The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Open accessAbstract
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses. EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival. RESULTS: Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths. CONCLUSIONS AND RELEVANCE: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [2]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“In melanoma, anti-PD-1 treatment was more effective in patients with smaller tumors (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“For example, patients with smaller tumors or low serum lactate dehydrogenase (LDH) levels at baseline have a better prognosis and are also more likely to respond to anti-PD-1 treatment (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Patients more likely to benefit from checkpoint immunotherapy include those with tumors demonstrating a high density of somatic mutations, elevated PD-L1 expression and/or are enriched with IFNγ transcriptional profiles (8–13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“Anti-PD-1 immunotherapy has shown efficacy in melanoma, but fewer than half of all melanoma patients treated with anti-PD-1 immunotherapy have a prolonged response5.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
- Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
- Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558,ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
Cited by
Sorted by citations
Items 301–400 of 1,000
Kim, H. J., Chang, J. S., Roh, M. R., Oh, B. H., Chung, K. Y., Shin, S. J., & Koom, W. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00835 · Cited by 49
Low doses in immunotherapy: Are they effective?
Prabhash, K., Patil, V. M., Noronha, V., Joshi, A. D., Abhyankar, A. V., Menon, N. S., Banavali, S. D., & Gupta, S. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_29_19 · Cited by 48
Bastacky, M. L., Wang, H., Fortman, D. D., Rahman, Z., Mascara, G. P., Brenner, T., Najjar, Y. G., Luke, J. J., Kirkwood, J. M., Zarour, H. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749064 · Cited by 49
Self-citationMelanoma and Nanotechnology-Based Treatment
Zeng, H., Li, J. X., Hou, K., Wu, Y., Chen, H., & Zeng, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.858185 · Cited by 49
Qu, C. F., Shao, X., Jia, R., Song, G., Shi, D., Wang, H., Wang, J., & An, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05483 · Cited by 49
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Wang, D. Y., Eroglu, Z., Özgün, A., Leger, P. D., Zhao, S., Ye, F., Luke, J. J., Joseph, R. W., Haq, R., Ott, P. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0287 · Cited by 52
Self-citationCombination Immunotherapy Development in Melanoma
Eggermont, A. M. M., Crittenden, M. R., & Wargo, J. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201131 · Cited by 47
The roles of exosomal immune checkpoint proteins in tumors
Cheng, X., Li, H., Li, R., Yin, L., Zhang, H., Huang, Z., Cheng, Z., Li, J., Wang, Z.-H., & Peng, H. (2021) · Military Medical Research · doi:10.1186/s40779-021-00350-3 · Cited by 48
Choi, F. D., Kraus, C. N., Elsensohn, A. N., Carley, S. K., Lehmer, L. M., Nguyen, R., Linden, K. G., & Shiu, J. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.077 · Cited by 46
Lubrano, S., Cervantes‐Villagrana, R. D., Faraji, F., Ramirez, S. I., Sato, K., Adame-Garcia, S. R., Officer, A., Arang, N., Rigiracciolo, D. C., Quiroz, P. Y. A., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.001 · Cited by 51
Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R. S., Idorn, M., Ahmad, S. M., Ellebæk, E., Müeller, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3172 · Cited by 46
Shao, K., McGettigan, S., Elenitsas, R., & Chu, E. Y. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.13059 · Cited by 46
Failing, J. J., Yan, Y., Porrata, L. F., & Markovic, S. N. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000404 · Cited by 44
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Han, N., Baghdadi, M., Ishikawa, K., Endo, H., Kobayashi, T., Wada, H., Imafuku, K., Hata, H., & Seino, K. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0060-2 · Cited by 46
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
Qu, J., Jiang, M., Wang, L., Zhao, D., Qin, K., Wang, Y., Tao, J., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109996 · Cited by 46
The Role for Chemotherapy in the Modern Management of Melanoma
Gupta, A., Gomes, F., & Lorigan, P. C. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0003 · Cited by 46
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Zhang, G., Wu, L. W., Mender, I., Barzily-Rokni, M., Hammond, M. R., Ope, O., Cheng, C., Vasilopoulos, T., Randell, S., Sadek, N. L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2773 · Cited by 44
Kothapalli, A., & Khattak, M. A. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000434 · Cited by 45
Checkpoints and beyond – Immunotherapy in colorectal cancer
Gutting, T., Burgermeister, E., Härtel, N., & Ebert, M. P. A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.003 · Cited by 48
Ribas, A., DAUD, A. I., Pavlick, A. C., Gonzalez, R. C., Lewis, K. D., Hamid, O., Gajewski, T. F., Puzanov, I. J., Wongchenko, M. J., Rooney, I. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4180 · Cited by 45
Self-citationCurrent Clinical Trial Landscape of OX40 Agonists
Yadav, R., & Redmond, W. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01265-5 · Cited by 45
Smithy, J. W., Moore, L. M., Pelekanou, V., Rehman, J., Gaule, P., Wong, P. F., Neumeister, V. M., Sznol, M., Kluger, H. M., & Rimm, D. L. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0229-2 · Cited by 43
Wang, M., Ma, X., Guo, L., & Xia, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s146286 · Cited by 45
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
Mina, L. A., Lim, S., Bahadur, S. W., & Firoz, A. T. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s184710 · Cited by 56
Signaling of Tumor-Derived sEV Impacts Melanoma Progression
Zebrowska, A., Widlak, P., Whiteside, T. L., & Pietrowska, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145066 · Cited by 44
Cummings, A. L., Gukasyan, J., Lu, H. Y., Grogan, T., Sunga, G. M., Fares, C. M., Hornstein, N. J., Zaretsky, J. M., Carroll, J., Bachrach, B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00140-1 · Cited by 46
Self-citationTargeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation
Čierniková, S., Kasperová, B. J., Drgoňa, Ľ., Smolková, B., Števurková, V., & Mego, M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100790 · Cited by 43
Surgical Management of Pancreatic Neuroendocrine Tumors
Sulciner, M. L., & Clancy, T. E. (2023) · Cancers · doi:10.3390/cancers15072006 · Cited by 43
Application of single-cell sequencing to the research of tumor microenvironment
Chen, S., Zhou, Z., Li, Y., Du, Y., & Chen, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285540 · Cited by 44
Lee, J., Lyle, M. K., Menzies, A. M., Chan, M. M. K., Lo, S., Clements, A., Carlino, M. S., Kefford, R. F., & Long, G. V. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12675 · Cited by 43
Self-citationDantonio, P. M., Klein, M., Freire, M. R. V. B., Araujo, C. D. N., Chiacetti, A. C., & Correa, R. G. (2018) · Bioscience Reports · doi:10.1042/bsr20180511 · Cited by 47
Ma, B., Wells, A. H., & Clark, A. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.021 · Cited by 44
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 44
Self-citationZiogas, D. C., Gkoufa, A., Cholongitas, Ε., Diamantopoulos, P. T., Anastasopoulou, A. N., Ascierto, P. A., & Gogas, H. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001322 · Cited by 43
PD-L2 based immune signature confers poor prognosis in HNSCC
Qiao, Y., Liu, C., Zhang, X., Zhou, Q., Li, Y., Xu, Y., Gao, Z., Xu, Y., Kong, L., Yang, A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1947569 · Cited by 43
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 42
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Ascierto, P. A., & McArthur, G. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1278-5 · Cited by 42
Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
Sahni, S., Valecha, G. K., & Sahni, A. (2018) · Cureus · doi:10.7759/cureus.3700 · Cited by 44
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers
Hyams, D. M., Cook, R. W., & Buzaid, A. C. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25319 · Cited by 41
Wang, X., Brea, L. T., & Yu, J. (2019) · PubMed Central · Cited by 43
Exosomes: Powerful weapon for cancer nano-immunoengineering
Pi, Y., Xia, B.-R., Jin, M., Jin, W., & Lou, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114487 · Cited by 42
ABCB5 promotes melanoma metastasis through enhancing NF-κB p65 protein stability
Wang, S., Tang, L., Lin, J., Shen, Z., Yao, Y., Wang, W. T., Tao, S., Gu, C., Ma, J., Xie, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.052 · Cited by 41
Zheng, L., Fan, Y., Wang, X., Yang, Z., Zhang, Y., Liu, T., Chen, M., Kang, S., Guo, S., Shi, Z., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202200811 · Cited by 42
Self-citationLong non-coding RNAs in cutaneous melanoma: clinical perspectives
Hulstaert, E., Brochez, L., Volders, P., Vandesompele, J., & Mestdagh, P. (2017) · Oncotarget · doi:10.18632/oncotarget.16478 · Cited by 40
Budczies, J., Bockmayr, M. L., Klauschen, F., Endris, V., Fröhling, S., Schirmacher, P., Denkert, C., & Stenzinger, A. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22468 · Cited by 41
Freeman, M. L., & Laks, S. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0003 · Cited by 41
Real-world experience with pembrolizumab in patients with advanced melanoma
Liu, F. X., Wanmei Ou, A., Diede, S. J., & Whitman, E. D. (2019) · Medicine · doi:10.1097/md.0000000000016542 · Cited by 42
Ridolfi, L., Rosa, F. D., Petracci, E., Tanda, E. T., Marra, E., Pigozzo, J., Marconcini, R., Guida, M., Cappellini, G. C. A., Gallizzi, G., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.12.012 · Cited by 40
Guyon, N., Garnier, D., Briand, J., Nadaradjane, A., Bougras-Cartron, G., Raimbourg, J., Campone, M., Heymann, D., Vallette, F. M., Frenel, J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03224-z · Cited by 40
Li, L., Miao, Q., Meng, F., Li, B., Xue, T., Fang, T., Zhang, Z., Zhang, J., Ye, X., Kang, Y., et al. (2021) · Theranostics · doi:10.7150/thno.48868 · Cited by 40
Networks of CD8+ T Cell Response Activation in Melanoma and Vitiligo
Fukuda, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.866703 · Cited by 42
Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases
Blakeway, E., Elshimy, N., Muinonen‐Martin, A., Marples, M., Mathew, B., & Mitra, A. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000587 · Cited by 39
Chhibber, A., Huang, L., Zhang, H., Xu, J., Cristescu, R., Liu, X., Mehrotra, D. V., Shen, J., Shaw, P. M., Hellmann, M. D., et al. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.006 · Cited by 39
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 40
Yu, X., Zhao, Z., & Jiang, Z. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac042 · Cited by 38
Using Antigen-Specific B Cells to Combine Antibody and T Cell–Based Cancer Immunotherapy
Wennhold, K., Thelen, M., Schlößer, H., Haustein, N., Reuter, S., Garcia-Marquez, M. A., Lechner, A., Kobold, S., Rataj, F., Utermöhlen, O., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0236 · Cited by 38
Daillère, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budínská, E., de Vries, I. J. M., Naccarati, A., Zitvogel, V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774298 · Cited by 41
Seith, F., Forschner, A., Weide, B., Gückel, B., Schwartz, M., Schwenck, J., Othman, M. I. A., Fenchel, M., Garbe, C., Nikolaou, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000656 · Cited by 38
Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer
Tamura, T., Yoshioka, Y., Sakamoto, S., Ichikawa, T., & Ochiya, T. (2021) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2021.06 · Cited by 39
Kunz, M., & Hölzel, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9657-1 · Cited by 38
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37
Interferon Signaling Is Frequently Downregulated in Melanoma
Alavi, S., Stewart, A., Kefford, R. F., Lim, S. Y., Shklovskaya, E., & Rizos, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01414 · Cited by 37
Self-citationImmune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
Nishida, T., Iijima, H., & Adachi, S. (2019) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v10.i2.17 · Cited by 40
Hayashi, Y., Hosoe, N., Takabayashi, K., Kamiya, K. J. L. L., Tsugaru, K., Shimozaki, K., Hirata, K., Fukuhara, K., Fukuhara, S., Mutaguchi, M., et al. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06441-w · Cited by 37
Efficacy of immune checkpoint inhibitors in different types of melanoma
Rossi, E., Schinzari, G., Maiorano, B. A., Indellicati, G., Stefani, A. D., Pagliara, M. M., Fragomeni, S. M., Luca, E. V. D., Sammarco, M. G., Garganese, G., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1771986 · Cited by 38
Wang, X., Ji, Q., Yan, X., Lian, B., Si, L., Chi, Z., Sheng, X., Kong, Y., Mao, L., Bai, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.546604 · Cited by 37
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00372 · Cited by 34
Self-citationEpigenetic mechanisms of tumor resistance to immunotherapy
Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36
Wekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 43
The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy
Puza, C. J., Bressler, E. S., Terando, A. M., Howard, J. H., Brown, M. C., Hanks, B. A., Salama, A. K. S., & Beasley, G. M. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.11.045 · Cited by 36
AACR Cancer Progress Report 2016
Davidson, N. E., Armstrong, S. A., Coussens, L. M., Cruz-Correa, M. R., DeBerardinis, R. J., Doroshow, J. H., Foti, M., Hwu, P., Kensler, T. W., Morrow, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1993 · Cited by 36
Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy
Bozward, A. G., Ronca, V., Osei‐Bordom, D., & Oo, Y. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711217 · Cited by 36
Lechner, M., Takahashi, Y., Turri‐Zanoni, M., Ferrari, M., Liu, J., Counsell, N., Mattavelli, D., Rampinelli, V., Vermi, W., Lombardi, D., et al. (2022) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0042-1750178 · Cited by 36
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Serkova, N. J., & Eckhardt, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00152 · Cited by 36
Malmberg, K., Sohlberg, E., Goodridge, J. P., & Ljunggren, H. (2017) · Immunogenetics · doi:10.1007/s00251-017-1011-9 · Cited by 36
Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis
Conway, K., Edmiston, S. N., Parker, J. S., Kuan, P. F., Tsai, Y., Groben, P. A., Zedek, D. C., SCOTT, G. A., Parrish, E., Hao, H., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.024 · Cited by 36
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 44
Axelrad, J. E., Hashash, J. G., & Itzkowitz, S. H. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.032 · Cited by 35
Organotypic three-dimensional assays based on human leiomyoma–derived matrices
Salo, T. A., Dourado, M. R., Sundquist, E., Apu, E. H., Alahuhta, I., Tuomainen, K., Vasara, J., & Al‐Samadi, A. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0482 · Cited by 35
Bianconi, A., Palmieri, G., Aruta, G., Monticelli, M., Zeppa, P., Tartara, F., Melcarne, A., Garbossa, D., & Cofano, F. (2023) · Biomedicines · doi:10.3390/biomedicines11061520 · Cited by 35
Buja, A., Sartor, G., Scioni, M., Vecchiato, A., Bolzan, M., Rebba, V. S., Chiarion‐Sileni, V., Palozzo, A. C., Montesco, M. C., Fiore, P. D., et al. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2830 · Cited by 35
Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy
Yu, X., Zhai, X., Wu, J., Feng, Q., Hu, C., Zhu, L., & Zhou, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166881 · Cited by 35
Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Espinosa, E., Márquez‐Rodas, I., Soria, A., Berrocal, A., Manzano, J. L., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.10 · Cited by 33
Anti-PD-1 Therapy-Associated Perforating Colitis
Celli, R., Kluger, H. M., & Zhang, X. (2018) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2018/3406437 · Cited by 34
Feld, E., & Mitchell, T. C. (2018) · Immunotherapy · doi:10.2217/imt-2017-0143 · Cited by 34
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Vargas, T. R., & Apétoh, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01181 · Cited by 37
Zhao, L., Zhuang, Y., Fu, K., Chen, P., Wang, Y., Zhuo, J., Liao, X., Chen, H., & Lin, Q. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04654-4 · Cited by 34
Martomo, S. A., Lü, D., Polonskaya, Z., Luna, X., Zhang, Z., Feldstein, S. F., Lumban-Tobing, R., Almstead, D. K., Miyara, F., & Patel, J. P. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0457 · Cited by 33
PD-1 blockade prevents the progression of oral carcinogenesis
Dong, Y., Wang, Z., Mao, F., Cai, L., Dan, H., Jiang, L., Zeng, X. Y., Li, T., Zhou, Y. J., & Chen, Q. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab035 · Cited by 34
Xie, X., Lv, J., Zhu, W., Tian, C., Li, J., Liu, J., Zhou, H., Sun, C., Hu, Z., & Li, X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101287 · Cited by 34
Self-citationMacrophages in melanoma: A double‑edged sword and targeted therapy strategies (Review)
Zhou, Q., Fang, T., Wei, S., Chai, S., Yang, H., Tao, M., & Cao, Y. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11577 · Cited by 35
Mycobacterium bovis BCG in metastatic melanoma therapy
Ruiz-Benitez, M., Bender, C. B., Oliveira, T. L., Schachtschneider, K. M., Collares, T. V., & Seixas, F. K. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10057-0 · Cited by 34
MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Lee, P.-J., Hung, C.-M., Yang, A.-J., Hou, C.-Y., Chou, H.-W., Chang, Y.-C., Chu, W.-C., Huang, W.-Y., Kuo, W.-C., Yang, C.-C., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2380061 · Cited by 33
In Situ Cocktail Nanovaccine for Cancer Immunotherapy
Liu, M., Xie, D., Hu, D., Zhang, R., Wang, Y., Tang, L., Zhou, B., Zhao, B., & Yang, L. (2023) · Advanced Science · doi:10.1002/advs.202207697 · Cited by 32
Hegde, U. P., & Mukherji, B. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2007-x · Cited by 33
Braun, D., Getahun, D. T., Chiu, V. Y., Coleman, A. L., Holland, G. N., Yu, F., Gordon, L. K., & Sun, M. M. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.12.013 · Cited by 33
Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
Georgantzoglou, N., Kokkali, S., Tsourouflis, G. S., & Theocharis, S. E. (2021) · Cancers · doi:10.3390/cancers13081798 · Cited by 33
Nagira, Y., Nagira, M., Nagai, R., Nogami, W., Hirata, M., Ueyama, A., Yoshida, T., Yoshikawa, M., Shinonome, S., Yoshida, H., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0570 · Cited by 32
Metadata
- Authors
- Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B., Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P., & Robert, C.
- Affiliations
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Westmead Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- South Texas Accelerated Research Therapeutics (US)
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Abramson Cancer Center (US)
- The University of Sydney (AU)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Institut Gustave Roussy (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Ribas, Antoni
- Hamid, Omid
- Daud, Adil
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Kefford, Richard
- Joshua, Anthony M.
- Patnaik, Amita
- Hwu, Wen-Jen
- Weber, Jeffrey S.
- Hersey, Peter
- Dronca, Roxana
- Joseph, Richard W.
- Zarour, Hassane
- Chmielowski, Bartosz
- Lawrence, Donald P.
- Algazi, Alain
- Rizvi, Naiyer A.
- Mateus, Christine
- Li, Xiaoyun Nicole
- Robert, Caroline
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1600
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2338494814
- Cited by
- 1,069
- References
- 22
- Citations by year
- 2026: 33 · 2025: 66 · 2024: 67 · 2023: 99 · 2022: 63 · 2021: 123 · 2020: 139 · 2019: 139 · 2018: 145 · 2017: 153 · 2016: 39
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, advanced melanoma, metastatic melanoma, anti-PD-1 therapy, anti-PD-1 monoclonal antibody, objective response rate, overall survival, progression-free survival, duration of response, ipilimumab, immune checkpoint inhibitors, treatment-naive patients, treatment-emergent adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Rate, Treatment Outcome, Disease Progression, Disease-Free Survival, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
